论文部分内容阅读
目的:研究风湿性心脏病并发心房颤动患者应用胺碘酮治疗的安全性。方法:将137例风湿性心脏病并发心房颤动患者,根据美国心脏病协会1992年修订的Jone标准分为显著风湿活动组:62例;可疑风湿活动组:47例;无风湿活动组:28例。137例均口服胺碘酮,观察室性心动过速的发生情况,分析室性心动过速与风湿活动、瓣膜病种类、心功能状态、二尖瓣瓣口面积及左房大小的关系。结果:多形性室性心动过速的发生与显著风湿活动有显著性关系,但与瓣膜病的种类、心功能状态、二尖瓣瓣膜口面积及左房大小无相关关系。结论:风湿性心脏病心房颤动患者存在风湿活动时,应慎用胺碘酮。
Objective: To study the safety of amiodarone in patients with rheumatic heart disease complicated with atrial fibrillation. Methods: One hundred and thirty-seven patients with rheumatic heart disease complicated with atrial fibrillation were divided into six groups according to Jone’s standard revised by the American Heart Association in 1992: 62 cases; suspicious rheumatic activity group: 47 cases; rheumatoid activity group: 28 cases . 137 cases were oral amiodarone observed ventricular tachycardia occurred, the analysis of ventricular tachycardia and rheumatic activity, valvular disease types, cardiac function, mitral valve area and left atrial size. Results: The incidence of pleomorphic ventricular tachycardia was significantly correlated with significant rheumatism, but not with the type of valvular disease, cardiac function, mitral valve orifice area and left atrial size. Conclusion: Amiodarone should be used with caution in the presence of rheumatic activity in patients with rheumatic heart disease and atrial fibrillation.